You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells

Citation Tools

Article menu

Download PDFPDF

Poster Presentation
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Morishima C, McNeel DG, Patel MR, et al
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells
Journal for ImmunoTherapy of Cancer 2014;2:P80. doi: 10.1186/2051-1426-2-S3-P80